GlassScriptPhysician profile
Sushama Mody
NPI 1760682173
$11,089.54
in general payments reported to CMS, 2019-2025
34 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,487 · 2020: $1,603 · 2021: $1,691 · 2022: $4,321 · 2023: $696 · 2024: $113 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $2,050.00 | 2022 | |
| Abbvie INC. | $1,279.76 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $1,129.09 | 2019-2023 | |
| Pfizer INC. | $996.27 | 2019-2023 | |
| Amgen INC. | $889.35 | 2019-2025 | Enbrel, Otezla, Tavneos |
| E.R. Squibb & Sons, L.L.C. | $610.21 | 2019-2025 | Sotyktu |
| Lilly USA, LLC | $522.16 | 2019-2023 | Taltz |
| Horizon Therapeutics Plc | $509.25 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $504.08 | 2019-2023 | Tremfya, Stelara, Remicade |
| Glaxosmithkline, LLC. | $401.74 | 2019-2024 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.45 | 2019-2022 | |
| Ucb, INC. | $228.27 | 2019-2023 | Cimzia |
| Progentec Diagnostics, INC. | $199.69 | 2020-2022 | |
| Genzyme Corporation | $188.87 | 2019-2022 | |
| Medexus Pharma, INC. | $159.29 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $147.22 | 2021-2023 | Lupkynis |
| Genentech USA, INC. | $117.92 | 2019-2020 | |
| Depuy Synthes Sales INC. | $113.52 | 2019-2022 | |
| Gilead Sciences, INC. | $110.03 | 2020 | |
| Octapharma USA, INC. | $95.53 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $72.80 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $65.21 | 2019-2021 | |
| Sobi, INC | $55.64 | 2021-2023 | |
| Fidia Pharma USA INC. | $52.67 | 2019-2023 | Triluron, Hymovis |
| Alexion Pharmaceuticals, INC. | $44.79 | 2020-2023 | Strensiq |
| Mallinckrodt Hospital Products INC. | $42.91 | 2021-2023 | Acthar |
| Daiichi Sankyo INC. | $41.40 | 2020 | |
| Boston Scientific Corporation | $25.15 | 2019 | |
| Fresenius Kabi USA, LLC | $15.79 | 2023 | |
| Antares Pharma, INC. | $15.00 | 2019 | |
| Merck Sharp & Dohme LLC | $14.85 | 2019 | |
| Mylan Institutional INC. | $14.07 | 2023 | Hulio |
| Teva Pharmaceuticals USA, INC. | $12.49 | 2022 | |
| Organon LLC | $10.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushama Mody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.